Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab. - Wikidata - awgldk - TriplyDB

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

http://www.wikidata.org/entity/Q37693888

about

Corneal neovascularization and biological therapy The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea.Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization.Recent drug therapies for corneal neovascularization.Infliximab eye drops treatment in corneal neovascularization.Therapeutic approaches for corneal neovascularization.Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.The effects of topical everolimus and sunitinib on corneal neovascularization.Photokinetic Drug Delivery: Near infrared (NIR) Induced Permeation Enhancement of Bevacizumab, Ranibizumab and Aflibercept through Human Sclera.Effect of Collagen Cross-Linking on Alkali Burn-Induced Corneal Neovascularization in Rabbits

P2860

Q26776229-C80913CF-3D74-4D17-90C3-6ECE56DE9D97 Q35827577-11735537-4D66-471D-8486-617A69034B89 Q38323786-06FC6738-F233-49D7-894D-38CE7CEB8CD8 Q38623872-04059204-0F8F-42FF-A509-E76006A75D5E Q38755418-849828E4-C75E-4062-9900-BCBFB0B7759B Q39295602-5CF74FBC-31FC-4B90-B72E-84307AF73994 Q40872769-8006A608-4CF3-4D40-8C82-33479D7B2012 Q47143268-69879B7C-A9B7-407E-8CB8-176DB17ABE27 Q50220412-3BA0E82B-2DC1-493D-B5AF-32C828C497A2 Q53546229-7E510EEF-CE6D-4F95-93EA-4657514C55BD Q55353695-A850C696-55D2-44B6-9AA5-05579B69C3A0 Q58578699-3F94FD05-E76F-42CC-AAA0-D3B41C47835B

P2860

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

http://www.wikidata.org/entity/Q37693888

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@en

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@nl

type

label

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@en

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@nl

prefLabel

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@en

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.

@nl

P1433

Q37693888-9C930823-D874-4782-A411-4C2B9D22AA69

P1476

Q37693888-3BAF9F17-025C-4979-9A7F-D5570A679598

P2093

Q37693888-5B425F89-1E32-4CE4-9BBB-B6A0B48EEE75

Q37693888-5F547DFE-1CF5-4946-BCD1-2D40182B97D2

Q37693888-9CB1B6E8-7F75-4279-8D26-3235351C1D7A

P2860

Q37693888-0C186144-7F85-4F44-8B58-64EB35A0C903

Q37693888-19563A45-3FBB-42D2-9A86-D90F2388A3F7

Q37693888-1FBDA85B-1D70-4499-95AD-AC34F03D03B8

Q37693888-2A895B91-A4A2-4087-9D99-BB64C6914E51

Q37693888-374F5434-74B6-4095-A06E-54928818E775

Q37693888-37F26570-D6FE-4B5A-B586-1343346FBAFA

Q37693888-3EA0DD67-BDE8-4F1B-84C7-130C00E8B61D

Q37693888-4BA89644-37D0-42AC-8BFD-699E1391DF9A

Q37693888-54E7E608-8C09-4450-A3D1-751D9E890E13

Q37693888-5A354E6C-591B-49B5-8744-5BACE0988B03

P304

Q37693888-15085A4C-2A67-4316-9E49-1C9F040289B1

P31

Q37693888-757427C2-01A5-46FB-BE7C-6A46B4002D7E

P356

Q37693888-B4DAAC35-DFA9-4375-B6CB-DC586513218B

P478

Q37693888-1AA7F792-4C7C-41D4-8B9F-DFD81CB67887

P50

Q37693888-F9149953-4B5B-4984-A290-7E41E4268FE9

P577

Q37693888-C61DBDC2-795B-49D3-BC77-577F29AEE499

P5875

Q37693888-9F2FB6A2-1F3C-4640-B4F5-A52042C13EA7

P698

Q37693888-F716AADF-0896-44A3-B6BD-78279ED25FAC

P921

Q37693888-819B4BAA-E0CA-4D41-A0B0-97A395BD1A11

Q37693888-BEBD6284-2A95-46FB-892E-435E79338101

P932

Q37693888-8F8BF8D7-8BC4-4141-9A68-DB9520E78525

P356

P1433

Journal of Ophthalmology

P1476

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab

@en

P2093

Katerina Liehneova

http://www.w3.org/2001/XMLSchema#string

Magdalena Vokrojova

http://www.w3.org/2001/XMLSchema#string

Pavel Studeny

http://www.w3.org/2001/XMLSchema#string

P2860

Corneal avascularity is due to soluble VEGF receptor-1

Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization

Corneal neovascularization.

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.

Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.

Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.

Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.

Corneal neovascularization: an anti-VEGF therapy review.

Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

P304

178132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/178132

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261957527

http://www.w3.org/2001/XMLSchema#string

P698

24778865

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

3981012

http://www.w3.org/2001/XMLSchema#string